[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603786":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Hemodialysis group",null,"Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.",{"label":13,"type":10,"description":14,"interventionNames":10},"Kidney transplant group","Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.",{"label":16,"type":10,"description":17,"interventionNames":10},"General population osteoporosis\u002Fosteopenia","Men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Nada Akad, Dr.","CONTACT","0040742015245","akadnada@gmail.com",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"University of Medicine and Pharmacy \"Grigore T. Popa\"","RECRUITING","Iași","Romania","RO",{"type":32,"coordinates":33},"Point",[34,35],27.6,47.16667,{"lat":35,"lon":34},[38],{"name":20,"role":21,"phone":10,"phoneExt":10,"email":23},{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Akad Nada","MD","100603786","assessment-of-mineral-and-bone-disorders-in-kidney-transplant-recipients-100603786",false,"NCT07141043","Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","Inclusion Criteria:\n\n1. HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.\n2. KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.\n3. GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.\n\nExclusion Criteria:\n\n1. HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen\u002Fanti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding.\n2. KTR group: The same as for HD + return to dialysis + acute graft rejection.\n3. GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (\\>7.5 mg Prednisone or equivalent for at least 3 months).",true,"ALL","20 Years","70 Years",{"count":55,"type":56},180,"ESTIMATED","OBSERVATIONAL","This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.",[60,61,62,63],"Hemodyalysis","Kidney Tansplant","Osteoporosis","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder",[65,62,66],"CKD-MBD","bone turnover markers","2025-08-18",{"date":69,"type":70},"2025-08-26","ACTUAL",{"date":72,"type":70},"2025-03-19",{"date":74,"type":56},"2027-06",{"name":5,"class":6},1]